Cantor Fitzgerald Reaffirms “Overweight” Rating for Keros Therapeutics (NASDAQ:KROS)

Cantor Fitzgerald reissued their overweight rating on shares of Keros Therapeutics (NASDAQ:KROS) in a research note released on Friday,Benzinga reports.

KROS has been the subject of several other research reports. Guggenheim began coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They set a “buy” rating and a $96.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a report on Thursday, November 7th. Bank of America lowered their price objective on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research report on Thursday, September 12th. Jefferies Financial Group began coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating on the stock. Finally, Scotiabank assumed coverage on Keros Therapeutics in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price target for the company. Twelve investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $88.89.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS opened at $55.92 on Friday. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of -10.73 and a beta of 1.23. The stock’s fifty day moving average price is $59.30 and its two-hundred day moving average price is $52.17. Keros Therapeutics has a one year low of $27.31 and a one year high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. Keros Therapeutics’s quarterly revenue was up 4750.0% compared to the same quarter last year. During the same period last year, the company posted ($1.33) EPS. On average, equities analysts anticipate that Keros Therapeutics will post -5.28 earnings per share for the current fiscal year.

Institutional Trading of Keros Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Keros Therapeutics by 7.9% in the first quarter. Vanguard Group Inc. now owns 1,545,758 shares of the company’s stock valued at $102,329,000 after acquiring an additional 113,563 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in shares of Keros Therapeutics by 14.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after purchasing an additional 324 shares in the last quarter. American International Group Inc. lifted its holdings in shares of Keros Therapeutics by 13.1% in the 1st quarter. American International Group Inc. now owns 12,653 shares of the company’s stock worth $838,000 after purchasing an additional 1,465 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its position in Keros Therapeutics by 117.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 5,217 shares of the company’s stock valued at $345,000 after purchasing an additional 2,822 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in Keros Therapeutics by 17.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock valued at $80,666,000 after purchasing an additional 176,803 shares in the last quarter. 71.56% of the stock is owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.